Literature DB >> 6185373

Identification and properties of cyclic nucleotide phosphodiesterases.

J A Beavo, R S Hansen, S A Harrison, R L Hurwitz, T J Martins, M C Mumby.   

Abstract

Mesh：

Substances：

Year:  1982        PMID： 6185373     DOI： 10.1016/0303-7207(82)90135-6

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN： 0303-7207            Impact factor:   4.102


× No keyword cloud information.
  29 in total

1.  Identification and characterization of a Ca2+-calmodulin-sensitive cyclic nucleotide phosphodiesterase in a human lymphoblastoid cell line.

Authors:  P M Epstein; S Moraski; R Hachisu
Journal:  Biochem J       Date:  1987-04-15       Impact factor: 3.857

2.  Identification of a noncatalytic cGMP-binding domain conserved in both the cGMP-stimulated and photoreceptor cyclic nucleotide phosphodiesterases.

Authors:  H Charbonneau; R K Prusti; H LeTrong; W K Sonnenburg; P J Mullaney; K A Walsh; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

3.  Strategic approaches to drug design. II. Modelling studies on phosphodiesterase substrates and inhibitors.

Authors:  A Davis; B H Warrington; J G Vinter
Journal:  J Comput Aided Mol Des       Date:  1987-07       Impact factor: 3.686

4.  Specific antibodies and the selective inhibitor ICI 118233 demonstrate that the hormonally stimulated 'dense-vesicle' and peripheral-plasma-membrane cyclic AMP phosphodiesterases display distinct tissue distributions in the rat.

Authors:  N J Pyne; N Anderson; B E Lavan; G Milligan; H G Nimmo; M D Houslay
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

5.  Identification and characterization of both the cytosolic and particulate forms of cyclic GMP-stimulated cyclic AMP phosphodiesterase from rat liver.

Authors:  N J Pyne; M E Cooper; M D Houslay
Journal:  Biochem J       Date:  1986-03-01       Impact factor: 3.857

6.  Immunological identification of the major platelet low-Km cAMP phosphodiesterase: probable target for anti-thrombotic agents.

Authors:  C H Macphee; S A Harrison; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

7.  The sites of phosphorylation by protein kinase C and an intact SH2 domain are required for the enhanced response to beta-adrenergic agonists in cells overexpressing c-src.

Authors:  J S Moyers; A H Bouton; S J Parsons
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

8.  Human lower oesophageal sphincter relaxation is associated with raised cyclic nucleotide content.

Authors:  M S Barnette; F C Barone; P J Fowler; M Grous; W J Price; H S Ormsbee
Journal:  Gut       Date:  1991-01       Impact factor: 23.059

9.  Characterization of a calmodulin-dependent high-affinity cyclic AMP and cyclic GMP phosphodiesterase from male mouse germ cells.

Authors:  R Geremia; P Rossi; D Mocini; R Pezzotti; M Conti
Journal:  Biochem J       Date:  1984-02-01       Impact factor: 3.857

10.  An assessment of the ability of insulin-stimulated cyclic AMP phosphodiesterase to decrease hepatocyte intracellular cyclic AMP concentrations.

Authors:  C M Heyworth; A V Wallace; S R Wilson; M D Houslay
Journal:  Biochem J       Date:  1984-08-15       Impact factor: 3.857
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.